Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
BMC Pulmonary Medicine|April 1, 2025
Characteristics and sex differences in bronchopulmonary dysplasia-related pulmonary hypertensionDansha Zhou, Ting Wang, Yuqin Chen, et al.
Plos One|August 5, 2015
Irisin Induces Angiogenesis in Human Umbilical Vein Endothelial Cells In Vitro and in Zebrafish Embryos In Vivo via Activation of the ERK Signaling PathwayFei Wu, Haibo Song, Yuan Zhang, et al.
Plos One|June 30, 2016
Protective Effect of Irisin on Atherosclerosis via Suppressing Oxidized Low Density Lipoprotein Induced Vascular Inflammation and Endothelial DysfunctionYuzhu Zhang, Qian Mu, Zheng Zhou, et al.
Scientific Reports|June 7, 2017
Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferaseJiyuan Zhou, Liuwei Song, Hong Zhao, et al.
Scientific Reports|February 18, 2024
Regression-based Chinese norms of number connection test A and digit symbol test for diagnosing minimal hepatic encephalopathyPeng Zhang, Danan Gan, Xiaoling Chi, et al.
Nature|May 14, 2025
Targeting symbionts by apolipoprotein L proteins modulates gut immunityTao Yang, Xiaohu Hu, Fei Cao, et al.
Journal of Clinical and Translational Hepatology|October 15, 2019
A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2aXinyue Chen, Qianguo Mao, Yao Xie, et al.
Cell Metabolism|October 10, 2024
Sensing steroid hormone 17α-hydroxypregnenolone by GPR56 enables protection from ferroptosis-induced liver injuryHui Lin, Chuanshun Ma, Xiao Zhuang, et al.
The Lancet. Gastroenterology & Hepatology|July 20, 2020
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)Lai Wei, Guiqiang Wang, Negar N Alami, et al.
Antiviral Therapy|October 22, 2020
Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE studyJidong Jia, Jia Shang, Hong Tang, et al.
Pageof 14